Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Inmune Bio Inc. (INMB:NASDAQ), powered by AI.
Inmune Bio Inc. is currently trading at $1.28. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Inmune Bio Inc. on Alpha Lenz.
View Inmune Bio Inc.'s valuation metrics on Alpha Lenz.
“Inmune Bio Inc.'s ROE is -165.2%. Explore profitability and growth together.”
Ask for details →Inmune Bio Inc. is a biotechnology company focused on the development of innovative therapies for modulating the immune system. The primary purpose of its research and development efforts is to create treatments that help in managing and potentially curing a range of conditions by targeting innate immune functions. This approach is significant in the medical field, particularly in autoimmune diseases, cancer, and neurodegenerative disorders, where the immune system's regulation can have profound impacts on disease progression and patient outcomes. By harnessing the body's own defense mechanisms, Inmune Bio Inc. aims to advance therapeutic solutions that are both effective and minimize adverse side effects. Operating in a rapidly evolving sector, the company holds an influential role in the biotechnology market, contributing to cutting-edge scientific advancements. By fostering collaborations with research institutions and leveraging its proprietary technologies, Inmune Bio Inc. continues to push the boundaries of immune-based treatments, offering hope for novel applications across different medical conditions.
“Inmune Bio Inc.'s ROE is -165.2%. Explore profitability and growth together.”
Ask for details →Inmune Bio Inc. (ticker: INMB) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 13 employees.
The current price is $1.28 with a P/E ratio of -x and P/B of -x.
ROE is -165.16% and operating margin is -61738.00%. Annual revenue is $50,000.